Behçet's Disease Characteristics and Treatment

Disease Overview

Behçet's disease is primarily caused by a complex interplay between genetic predisposition and environmental triggers that lead to dysregulated immune responses, resulting in systemic vasculitis 1

Behçet's disease is more common in Turkey, with a prevalence of 80-370 cases per 100,000 persons, compared to only 1-3 cases per million in the United States 2, 3, 4
The disease is characterized by oral ulceration plus at least two of: recurrent genital ulceration, uveitis/retinal vasculitis, or specific skin lesions 2, 3, 4
Vascular involvement occurs in approximately one-third of patients, affecting both arteries and veins 2, 3, 4

Treatment should be individualized based on organ involvement and disease severity 1
Avoid cyclosporine A in patients with central nervous system involvement due to potential neurotoxicity 1
Anticoagulants should generally be avoided in Behçet's disease with venous thrombosis due to bleeding risk, especially with coexisting pulmonary arterial aneurysms 1
Young men with early disease onset have higher risk of severe disease and may benefit from early systemic immunosuppression 1
Post-thrombotic syndrome is frequent with recurrent deep vein thrombosis and may result in difficult-to-treat leg ulcers 1

Behçet's disease can occasionally occur alongside other autoimmune disorders, according to the European League Against Rheumatism 5
Unlike type 1 diabetes, Behçet's disease does not have strong established associations with other autoimmune conditions, such as thyroid disease, celiac disease, and autoimmune gastritis, as stated by the American Diabetes Association 6

Pre-existing autoimmune rheumatic and/or systemic diseases should not preclude treatment for Behçet's disease, as recommended by the European League Against Rheumatism 5
In patients with cancer immunotherapy receiving checkpoint inhibitors who have pre-existing Behçet's disease, no flares were reported, according to the European League Against Rheumatism 5
When managing patients with both Behçet's disease and other autoimmune conditions, baseline immunosuppressive regimens should be kept at the lowest effective dose possible, as suggested by the European League Against Rheumatism 5

Pharmacological agents utilized for treatment of Behçet's disease include corticosteroids, colchicine, azathioprine, and TNF-α inhibitors, as reported by the British Society for Rheumatology 7